Marotta Asset Management cut its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 13.4% in the third quarter, HoldingsChannel reports. The fund owned 57,881 shares of the exchange traded fund’s stock after selling 8,929 shares during the quarter. SPDR S&P Biotech ETF accounts for 1.5% of Marotta Asset Management’s portfolio, making the stock its 25th biggest holding. Marotta Asset Management’s holdings in SPDR S&P Biotech ETF were worth $9,127,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of XBI. Bank of America Corp DE increased its holdings in shares of SPDR S&P Biotech ETF by 13.3% in the 1st quarter. Bank of America Corp DE now owns 14,518,027 shares of the exchange traded fund’s stock valued at $1,854,388,000 after purchasing an additional 1,700,851 shares during the period. Avoro Capital Advisors LLC purchased a new position in SPDR S&P Biotech ETF during the fourth quarter valued at approximately $256,053,000. OMERS ADMINISTRATION Corp grew its position in SPDR S&P Biotech ETF by 42,425.2% during the fourth quarter. OMERS ADMINISTRATION Corp now owns 1,190,707 shares of the exchange traded fund’s stock valued at $145,147,000 after purchasing an additional 1,187,907 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its stake in SPDR S&P Biotech ETF by 61.4% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 691,000 shares of the exchange traded fund’s stock valued at $84,254,000 after buying an additional 263,000 shares during the period. Finally, Hsbc Holdings PLC increased its stake in SPDR S&P Biotech ETF by 7.8% in the 4th quarter. Hsbc Holdings PLC now owns 638,529 shares of the exchange traded fund’s stock valued at $78,049,000 after buying an additional 46,339 shares during the period.
SPDR S&P Biotech ETF Trading Down 0.1%
XBI stock traded down $0.08 during midday trading on Friday, reaching $154.43. The company had a trading volume of 8,742,205 shares, compared to its average volume of 9,099,798. The company has a 50 day moving average of $158.24 and a two-hundred day moving average of $144.85. The company has a market capitalization of $10.22 billion, a P/E ratio of 11.47 and a beta of 0.84. SPDR S&P Biotech ETF has a 1 year low of $102.55 and a 1 year high of $169.89.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
